Figure 5.
Probability of survival according to Kaplan-Meier estimates in “diagnosis code-based possible malignancy-associated HLH.” (A) Overall probability of survival in all 316 patients. (B) Overall probability of survival in all 316 patients shown separately for the time periods 1997 to 2007 and 2008 to 2018. (C) Overall probability of survival in patients diagnosed with HLH and B-cell lymphoma (n = 94), NK/T-cell lymphoma (n = 52), or Hodgkin lymphoma (n = 18) from 1997 to 2018. (D) Overall probability of survival in patients diagnosed with HLH and myeloid leukemia (n = 49), lymphocytic leukemia (n = 42), or solid tumors (n = 34) from 1997 to 2018. The generalized Wilcoxon test was used to compare the probability of survival.

Probability of survival according to Kaplan-Meier estimates in “diagnosis code-based possible malignancy-associated HLH.” (A) Overall probability of survival in all 316 patients. (B) Overall probability of survival in all 316 patients shown separately for the time periods 1997 to 2007 and 2008 to 2018. (C) Overall probability of survival in patients diagnosed with HLH and B-cell lymphoma (n = 94), NK/T-cell lymphoma (n = 52), or Hodgkin lymphoma (n = 18) from 1997 to 2018. (D) Overall probability of survival in patients diagnosed with HLH and myeloid leukemia (n = 49), lymphocytic leukemia (n = 42), or solid tumors (n = 34) from 1997 to 2018. The generalized Wilcoxon test was used to compare the probability of survival.

Close Modal

or Create an Account

Close Modal
Close Modal